drugset / Trial / NCT04498390

A Safety Study of LY3493269 in Healthy Participants

NCT04498390

Phase 1 Completed 40 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3493269 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 10 weeks and may include 12 visits, including five nights in a row in the clinical research center.

Timeline

Start
2020-09-03
Primary completion
2020-12-28
Completion
2020-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3493269 Unknown 8 mg Oral
Subject LY3493269 Unknown 24 mg Oral
Subject LY3493269 Unknown 48 mg Oral

Indications

No indication recorded.